{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:42Z","timestamp":1791357342119,"version":"4.3.1"},"publisher-location":"Cham","reference-count":184,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030109486","type":"print"},{"value":"9783030109493","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/164_2018_164","type":"book-chapter","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T20:21:41Z","timestamp":1551817301000},"page":"145-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Serotonin and Norepinephrine Reuptake Inhibitors"],"prefix":"10.1007","author":[{"given":"Richard C.","family":"Shelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"164_CR1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/gps.4088","volume":"29","author":"KJ Alaka","year":"2014","unstructured":"Alaka KJ, Noble W, Montejo A, Duenas H, Munshi A, Strawn JR, Lenox-Smith A, Ahl J, Bidzan L, Dorn B, Ball S (2014) Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 29:978\u2013986","journal-title":"Int J Geriatr Psychiatry"},{"key":"164_CR2","volume-title":"Savella prescribing information","author":"Allergan Plc","year":"2016","unstructured":"Allergan Plc (2016) Savella prescribing information. Allergan Plc, Irvine"},{"key":"164_CR3","volume-title":"Fetzima prescribing information","author":"Allergan Plc","year":"2017","unstructured":"Allergan Plc (2017) Fetzima prescribing information. Allergan Plc, Irvine"},{"key":"164_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/hup.602","volume":"19","author":"C Allgulander","year":"2004","unstructured":"Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387\u2013396","journal-title":"Hum Psychopharmacol"},{"key":"164_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00444686","volume":"98","author":"M Ansseau","year":"1989","unstructured":"Ansseau M, von Frenckell R, Mertens C, de Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Darimont P, Dejaiffe G et al (1989) Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 98:163\u2013168","journal-title":"Psychopharmacology"},{"key":"164_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4088\/JCP.12m08197","volume":"74","author":"GM Asnis","year":"2013","unstructured":"Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM (2013) Efficacy and safety of levomilnacipran sustained release 40\u00a0mg, 80\u00a0mg, or 120\u00a0mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74:242\u2013248","journal-title":"J Clin Psychiatry"},{"key":"164_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0028-3908(92)90025-K","volume":"31","author":"MB Assie","year":"1992","unstructured":"Assie MB, Charveron M, Palmier C, Puozzo C, Moret C, Briley M (1992) Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 31:149\u2013155","journal-title":"Neuropharmacology"},{"key":"164_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/cap.2013.0146","volume":"24","author":"SD Atkinson","year":"2014","unstructured":"Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS (2014) A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:180\u2013189","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"164_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","volume":"70","author":"AL Auclair","year":"2013","unstructured":"Auclair AL, Martel JC, Assie MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O\u2019Connor JA, Depoortere R (2013) Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70:338\u2013347","journal-title":"Neuropharmacology"},{"key":"164_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1503\/jpn.130040","volume":"39","author":"D Bakish","year":"2014","unstructured":"Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A (2014) Levomilnacipran ER 40\u00a0mg and 80\u00a0mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci 39:40\u201349","journal-title":"J Psychiatry Neurosci"},{"key":"164_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0006-8993(94)90519-3","volume":"668","author":"P Barone","year":"1994","unstructured":"Barone P, Moret C, Briley M, Fillion G (1994) Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain. Brain Res 668:129\u2013143","journal-title":"Brain Res"},{"key":"164_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0893-133X(99)00076-7","volume":"21","author":"N Bel","year":"1999","unstructured":"Bel N, Artigas F (1999) Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology 21:745\u2013754","journal-title":"Neuropsychopharmacology"},{"key":"164_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013372","volume":"7","author":"A Berard","year":"2017","unstructured":"Berard A, Zhao JP, Sheehy O (2017) Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open 7:e013372","journal-title":"BMJ Open"},{"key":"164_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0924-977X(02)00173-6","volume":"13","author":"P Blier","year":"2003","unstructured":"Blier P (2003) The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13:57\u201366","journal-title":"Eur Neuropsychopharmacol"},{"key":"164_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1192\/bjp.187.4.352","volume":"187","author":"J Bradwejn","year":"2005","unstructured":"Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005) Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352\u2013359","journal-title":"Br J Psychiatry"},{"key":"164_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jama.300.9.1025","volume":"300","author":"JA Bridge","year":"2008","unstructured":"Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ (2008) Suicide trends among youths aged 10 to 19\u00a0years in the United States, 1996-2005. JAMA 300:1025\u20131026","journal-title":"JAMA"},{"issue":"Suppl 4","key":"164_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00004850-199609004-00002","volume":"11","author":"M Briley","year":"1996","unstructured":"Briley M, Prost JF, Moret C (1996) Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11(Suppl 4):9\u201314","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","volume":"25","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871\u2013880","journal-title":"Neuropsychopharmacology"},{"key":"164_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0924-977X(93)90274-P","volume":"3","author":"J Caron","year":"1993","unstructured":"Caron J, Libersa C, Hazard JR, Lacroix D, Facq E, Guedon-Moreau L, Fautrez V, Solles A, Puozzo C, Kacet S et al (1993) Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 3:493\u2013500","journal-title":"Eur Neuropsychopharmacol"},{"key":"164_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMoa052744","volume":"354","author":"CD Chambers","year":"2006","unstructured":"Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579\u2013587","journal-title":"N Engl J Med"},{"key":"164_CR21","first-page":"Cd006533","volume":"10","author":"A Cipriani","year":"2012","unstructured":"Cipriani A, Koesters M, Furukawa TA, Nose M, Purgato M, Omori IM, Trespidi C, Barbui C (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 10:Cd006533","journal-title":"Cochrane Database Syst Rev"},{"key":"164_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","volume":"388","author":"A Cipriani","year":"2016","unstructured":"Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P (2016) Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 388:881\u2013890","journal-title":"Lancet"},{"key":"164_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00004850-199409000-00001","volume":"9","author":"GE Clerc","year":"1994","unstructured":"Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 9:139\u2013143","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1542\/peds.2013-0923","volume":"133","author":"WO Cooper","year":"2014","unstructured":"Cooper WO, Callahan ST, Shintani A, Fuchs DC, Shelton RC, Dudley JA, Graves AJ, Ray WA (2014) Antidepressants and suicide attempts in children. Pediatrics 133:204\u2013210","journal-title":"Pediatrics"},{"key":"164_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4088\/JCP.v59n0703","volume":"59","author":"J Costa e Silva","year":"1998","unstructured":"Costa e Silva J (1998) Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59:352\u2013357","journal-title":"J Clin Psychiatry"},{"key":"164_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/10401239709147791","volume":"9","author":"LA Cunningham","year":"1997","unstructured":"Cunningham LA (1997) Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 9:157\u2013164","journal-title":"Ann Clin Psychiatry"},{"key":"164_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00004714-199404000-00003","volume":"14","author":"LA Cunningham","year":"1994","unstructured":"Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E (1994) A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14:99\u2013106","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4088\/JCP.v60n0805","volume":"60","author":"JR Davidson","year":"1999","unstructured":"Davidson JR, DuPont RL, Hedges D, Haskins JT (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528\u2013535","journal-title":"J Clin Psychiatry"},{"key":"164_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.euroneuro.2008.05.002","volume":"18","author":"JR Davidson","year":"2008","unstructured":"Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM (2008) Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 18:673\u2013681","journal-title":"Eur Neuropsychopharmacol"},{"key":"164_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1124\/jpet.106.103382","volume":"318","author":"DC Deecher","year":"2006","unstructured":"Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657\u2013665","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/1099-1077(200006)15:4<255::AID-HUP165>3.0.CO;2-V","volume":"15","author":"A Delini-Stula","year":"2000","unstructured":"Delini-Stula A (2000) Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol 15:255\u2013260","journal-title":"Hum Psychopharmacol"},{"key":"164_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/BF03189334","volume":"23","author":"D Deprez","year":"1998","unstructured":"Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998) Which bioequivalence study for a racemic drug? Application to milnacipran. Eur J Drug Metab Pharmacokinet 23:166\u2013171","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"164_CR33","volume":"3","author":"S Derry","year":"2012","unstructured":"Derry S, Gill D, Phillips T, Moore RA (2012) Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 3:CD008244","journal-title":"Cochrane Database Syst Rev"},{"key":"164_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0022-3956(02)00060-2","volume":"36","author":"MJ Detke","year":"2002","unstructured":"Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002) Duloxetine 60\u00a0mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383\u2013390","journal-title":"J Psychiatr Res"},{"key":"164_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0149-2918(00)88287-9","volume":"21","author":"TR Einarson","year":"1999","unstructured":"Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21:296\u2013308","journal-title":"Clin Ther"},{"key":"164_CR36","volume-title":"Cymbalta prescribing information","author":"Eli Lilly and Company","year":"2016","unstructured":"Eli Lilly and Company (2016) Cymbalta prescribing information. Eli Lilly and Company, Indianapolis"},{"key":"164_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1089\/cap.2013.0096","volume":"24","author":"GJ Emslie","year":"2014","unstructured":"Emslie GJ, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS (2014) A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24:170\u2013179","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"164_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/cap.2014.0076","volume":"25","author":"GJ Emslie","year":"2015","unstructured":"Emslie GJ, Wells TG, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS (2015) Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 25:293\u2013305","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"164_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0893-133X(94)00093-F","volume":"12","author":"EA Engleman","year":"1995","unstructured":"Engleman EA, Perry KW, Mayle DA, Wong DT (1995) Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 12:287\u2013295","journal-title":"Neuropsychopharmacology"},{"key":"164_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1471-4159.1996.66020599.x","volume":"66","author":"EA Engleman","year":"1996","unstructured":"Engleman EA, Robertson DW, Thompson DC, Perry KW, Wong DT (1996) Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66:599\u2013603","journal-title":"J Neurochem"},{"issue":"Suppl 1","key":"164_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1520-6394(2000)12:1+<30::AID-DA4>3.0.CO;2-G","volume":"12","author":"L Ereshefsky","year":"2000","unstructured":"Ereshefsky L, Dugan D (2000) Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 12(Suppl 1):30\u201344","journal-title":"Depress Anxiety"},{"key":"164_CR42","first-page":"574","volume":"56","author":"JP Feighner","year":"1995","unstructured":"Feighner JP (1995) Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56:574\u2013579","journal-title":"J Clin Psychiatry"},{"key":"164_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0165-0327(97)00109-2","volume":"47","author":"JP Feighner","year":"1998","unstructured":"Feighner JP, Entsuah AR, McPherson MK (1998) Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 47:55\u201362","journal-title":"J Affect Disord"},{"issue":"Suppl 26","key":"164_CR44","first-page":"10","volume":"62","author":"IN Ferrier","year":"2001","unstructured":"Ferrier IN (2001) Characterizing the ideal antidepressant therapy to achieve remission. J Clin Psychiatry 62(Suppl 26):10\u201315","journal-title":"J Clin Psychiatry"},{"key":"164_CR45","volume-title":"Review and evaluation of pharmacology\/toxicology data: desvenlafaxine","author":"LH Fossom","year":"2008","unstructured":"Fossom LH (2008) Review and evaluation of pharmacology\/toxicology data: desvenlafaxine. US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring"},{"key":"164_CR46","first-page":"132","volume":"269","author":"RW Fuller","year":"1994","unstructured":"Fuller RW, Hemrick-Luecke SK, Snoddy HD (1994) Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther 269:132\u2013136","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0002-9343(00)00545-3","volume":"109","author":"BF Gage","year":"2000","unstructured":"Gage BF, Fihn SD, White RH (2000) Management and dosing of warfarin therapy. Am J Med 109:481\u2013488","journal-title":"Am J Med"},{"key":"164_CR48","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","volume":"283","author":"AJ Gelenberg","year":"2000","unstructured":"Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082\u20133088","journal-title":"JAMA"},{"key":"164_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3928\/0048-5713-19970201-05","volume":"27","author":"WJ Giakas","year":"1997","unstructured":"Giakas WJ, Davis JM (1997) Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatr Ann 27:85\u201392","journal-title":"Psychiatr Ann"},{"key":"164_CR50","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1176\/ajp.2006.163.11.1898","volume":"163","author":"RD Gibbons","year":"2006","unstructured":"Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163:1898\u20131904","journal-title":"Am J Psychiatry"},{"key":"164_CR51","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","volume":"164","author":"RD Gibbons","year":"2007","unstructured":"Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ (2007) Early evidence on the effects of regulators\u2019 suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356\u20131363","journal-title":"Am J Psychiatry"},{"key":"164_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0893-133X(99)00035-4","volume":"21","author":"A Gobert","year":"1999","unstructured":"Gobert A, Millan MJ (1999a) Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (\u2212)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology 21:268\u2013284","journal-title":"Neuropsychopharmacology"},{"key":"164_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0028-3908(98)00188-9","volume":"38","author":"A Gobert","year":"1999","unstructured":"Gobert A, Millan MJ (1999b) Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38:315\u2013317","journal-title":"Neuropharmacology"},{"key":"164_CR54","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1046\/j.1471-4159.1997.69062616.x","volume":"69","author":"A Gobert","year":"1997","unstructured":"Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1997) Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69:2616\u20132619","journal-title":"J Neurochem"},{"key":"164_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4088\/JCP.v63n0309","volume":"63","author":"DJ Goldstein","year":"2002","unstructured":"Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225\u2013231","journal-title":"J Clin Psychiatry"},{"key":"164_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0168-0102(97)00092-8","volume":"29","author":"JL Gongora-Alfaro","year":"1997","unstructured":"Gongora-Alfaro JL, Hernandez-Lopez S, Flores-Hernandez J, Galarraga E (1997) Firing frequency modulation of substantia nigra reticulata neurons by 5-hydroxytryptamine. Neurosci Res 29:225\u2013231","journal-title":"Neurosci Res"},{"key":"164_CR57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-2007-979548","volume":"29","author":"G Grunder","year":"1996","unstructured":"Grunder G, Wetzel H, Schlosser R, Benkert O (1996) Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-h monitoring. Pharmacopsychiatry 29:72\u201378","journal-title":"Pharmacopsychiatry"},{"key":"164_CR58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","volume":"22","author":"J Hartford","year":"2007","unstructured":"Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167\u2013174","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/archpsyc.57.5.503","volume":"57","author":"AT Harvey","year":"2000","unstructured":"Harvey AT, Rudolph RL, Preskorn SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503\u2013509","journal-title":"Arch Gen Psychiatry"},{"key":"164_CR60","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","volume":"50","author":"W Hauser","year":"2011","unstructured":"Hauser W, Petzke F, Uceyler N, Sommer C (2011) Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 50:532\u2013543","journal-title":"Rheumatology (Oxford)"},{"key":"164_CR61","doi-asserted-by":"publisher","first-page":"49.e41","DOI":"10.1016\/j.ajog.2012.04.028","volume":"207","author":"RM Hayes","year":"2012","unstructured":"Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, Mitchel E, Hartert TV (2012) Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 207:49.e41\u201349.e49","journal-title":"Am J Obstet Gynecol"},{"key":"164_CR62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1046\/j.1365-2125.2000.00124.x","volume":"49","author":"I Hindmarch","year":"2000","unstructured":"Hindmarch I, Rigney U, Stanley N, Briley M (2000) Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 49:118\u2013125","journal-title":"Br J Clin Pharmacol"},{"key":"164_CR63","volume-title":"Principles and practice of psychopharmacother","author":"PG Janicak","year":"2001","unstructured":"Janicak PG, Davis J, Preskorn SH, Ayd FJ (2001) Principles and practice of psychopharmacother. Lippincott Williams & Wilkins, Philadelphia"},{"key":"164_CR64","first-page":"25","volume":"16","author":"T Kasahara","year":"1996","unstructured":"Kasahara T, Ishigooka J, Nagata E, Murasaki M, Miura S (1996) Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant. Nihon Shinkei Seishin Yakurigaku Zasshi 16:25\u201331","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"164_CR65","first-page":"278","volume":"277","author":"K Kasamo","year":"1996","unstructured":"Kasamo K, Blier P, De Montigny C (1996) Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 277:278\u2013286","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 4","key":"164_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00004850-199609004-00005","volume":"11","author":"S Kasper","year":"1996","unstructured":"Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11(Suppl 4):35\u201339","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR67","first-page":"1067","volume":"272","author":"A Katoh","year":"1995","unstructured":"Katoh A, Eigyo M, Ishibashi C, Naitoh Y, Takeuchi M, Ibii N, Ikeda M, Matsushita A (1995) Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. J Pharmacol Exp Ther 272:1067\u20131075","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JCP.0000000000000100","volume":"34","author":"A Khan","year":"2014","unstructured":"Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT (2014) Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24\u00a0weeks with desvenlafaxine 50\u00a0mg\/d. J Clin Psychopharmacol 34:365\u2013368","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR69","first-page":"177","volume":"272","author":"T Kihara","year":"1995","unstructured":"Kihara T, Ikeda M (1995) Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272:177\u2013183","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","volume":"32","author":"KJ Klamerus","year":"1992","unstructured":"Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 32:716\u2013724","journal-title":"J Clin Pharmacol"},{"key":"164_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/sj.npp.1300996","volume":"31","author":"DF Klein","year":"2006","unstructured":"Klein DF (2006) The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 31:689\u2013699","journal-title":"Neuropsychopharmacology"},{"key":"164_CR72","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","volume":"50","author":"MP Knadler","year":"2011","unstructured":"Knadler MP, Lobo E, Chappell J, Bergstrom R (2011) Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 50:281\u2013294","journal-title":"Clin Pharmacokinet"},{"key":"164_CR73","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.4088\/JCP.v68n0706","volume":"68","author":"JH Kocsis","year":"2007","unstructured":"Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB (2007) Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 68:1014\u20131023","journal-title":"J Clin Psychiatry"},{"key":"164_CR74","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jad.2015.12.058","volume":"193","author":"SG Kornstein","year":"2016","unstructured":"Kornstein SG, Gommoll C, Chen C, Kramer K (2016) The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD. J Affect Disord 193:137\u2013143","journal-title":"J Affect Disord"},{"key":"164_CR75","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1345\/aph.1P218","volume":"44","author":"JA Kyle","year":"2010","unstructured":"Kyle JA, Dugan BD, Testerman KK (2010) Milnacipran for treatment of fibromyalgia. Ann Pharmacother 44:1422\u20131429","journal-title":"Ann Pharmacother"},{"key":"164_CR2005","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00004714-199702000-00016","volume":"17","author":"P Landry","year":"1997","unstructured":"Landry P, Roy L (1997) Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol 17:60\u201361","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/s-0035-1555879","volume":"48","author":"ZG Laoutidis","year":"2015","unstructured":"Laoutidis ZG, Kioulos KT (2015) Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry 48:187\u2013199","journal-title":"Pharmacopsychiatry"},{"key":"164_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bcpt.12497","volume":"118","author":"D Lassen","year":"2016","unstructured":"Lassen D, Ennis ZN, Damkier P (2016) First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol Toxicol 118:32\u201336","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"Suppl 4","key":"164_CR78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00004850-199609004-00004","volume":"11","author":"Y Lecrubier","year":"1996","unstructured":"Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V (1996) Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 11(Suppl 4):29\u201333","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR79","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1600-0447.1997.tb09953.x","volume":"96","author":"E Leinonen","year":"1997","unstructured":"Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R (1997) Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 96:497\u2013504","journal-title":"Acta Psychiatr Scand"},{"key":"164_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/YIC.0b013e3282f424c2","volume":"23","author":"AJ Lenox-Smith","year":"2008","unstructured":"Lenox-Smith AJ, Jiang Q (2008) Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 23:113\u2013119","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR81","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","volume":"62","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Gelenberg AJ, Munjack D (2005a) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190\u2013198","journal-title":"Arch Gen Psychiatry"},{"key":"164_CR82","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4088\/JCP.v66n0213","volume":"66","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238\u2013247","journal-title":"J Clin Psychiatry"},{"key":"164_CR83","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4088\/JCP.08m04238","volume":"70","author":"MR Liebowitz","year":"2009","unstructured":"Liebowitz MR, Asnis G, Mangano R, Tzanis E (2009) A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 70:550\u2013561","journal-title":"J Clin Psychiatry"},{"key":"164_CR84","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(SICI)1520-636X(2000)12:1<26::AID-CHIR5>3.0.CO;2-Z","volume":"12","author":"H Liu","year":"2000","unstructured":"Liu H, Hoff BH, Anthonsen T (2000) Chemo-enzymatic synthesis of the antidepressant duloxetine and its enantiomer. Chirality 12:26\u201329","journal-title":"Chirality"},{"key":"164_CR85","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00003088-200847020-00003","volume":"47","author":"ED Lobo","year":"2008","unstructured":"Lobo ED, Loghin C, Knadler MP, Quinlan T, Zhang L, Chappell J, Lucas R, Bergstrom RF (2008) Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet 47:103\u2013109","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 4","key":"164_CR86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00004850-199609004-00006","volume":"11","author":"J Lopez-Ibor","year":"1996","unstructured":"Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996) Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11(Suppl 4):41\u201346","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR87","first-page":"Cd007115","volume":"1","author":"MP Lunn","year":"2014","unstructured":"Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 1:Cd007115","journal-title":"Cochrane Database Syst Rev"},{"key":"164_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3810\/pgm.1999.07.611","volume":"106","author":"RB Lydiard","year":"1999","unstructured":"Lydiard RB (1999) Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies. Postgrad Med 106:17\u201323","journal-title":"Postgrad Med"},{"key":"164_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000118596","volume":"22","author":"JP Macher","year":"1989","unstructured":"Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP (1989) Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77\u201382","journal-title":"Neuropsychobiology"},{"key":"164_CR90","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s007020070022","volume":"107","author":"J Maj","year":"2000","unstructured":"Maj J, Rogoz Z, Dlaboga D, Dziedzicka-Wasylewska M (2000) Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems. J Neural Transm (Vienna) 107:1345\u20131359","journal-title":"J Neural Transm (Vienna)"},{"key":"164_CR91","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.biopsych.2007.02.025","volume":"62","author":"JS March","year":"2007","unstructured":"March JS, Entusah AR, Rynn M, Albano AM, Tourian KA (2007) A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 62:1149\u20131154","journal-title":"Biol Psychiatry"},{"key":"164_CR92","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/17425255.4.3.281","volume":"4","author":"RS McIntyre","year":"2008","unstructured":"McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, Lourenco MT, Konarski JZ, Kennedy SH (2008) The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 4:281\u2013285","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"164_CR93","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4088\/JCP.v61n0204","volume":"61","author":"OP Mehtonen","year":"2000","unstructured":"Mehtonen OP, Sogaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 61:95\u2013100","journal-title":"J Clin Psychiatry"},{"key":"164_CR94","first-page":"169","volume":"29","author":"J Mendels","year":"1993","unstructured":"Mendels J, Johnston R, Mattes J, Riesenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169\u2013174","journal-title":"Psychopharmacol Bull"},{"key":"164_CR95","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.tips.2006.05.004","volume":"27","author":"JA Mic\u00f3","year":"2006","unstructured":"Mic\u00f3 JA, Ardid D, Berrocoso E, Eschalier A (2006) Antidepressants and pain. Trends Pharmacol Sci 27:348\u2013354","journal-title":"Trends Pharmacol Sci"},{"key":"164_CR96","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/026988110201600311","volume":"16","author":"D Mochizuki","year":"2002","unstructured":"Mochizuki D, Hokonohara T, Kawasaki K, Miki N (2002a) Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A autoreceptors but not postsynaptic 5-HT1A receptors. J Psychopharmacol 16:253\u2013260","journal-title":"J Psychopharmacol"},{"key":"164_CR97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00213-002-1111-5","volume":"162","author":"D Mochizuki","year":"2002","unstructured":"Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N (2002b) Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology 162:323\u2013332","journal-title":"Psychopharmacology"},{"key":"164_CR98","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0028-3908(98)00083-5","volume":"37","author":"R Mongeau","year":"1998","unstructured":"Mongeau R, Weiss M, de Montigny C, Blier P (1998) Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 37:905\u2013918","journal-title":"Neuropharmacology"},{"issue":"Suppl 4","key":"164_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00004850-199609004-00007","volume":"11","author":"SA Montgomery","year":"1996","unstructured":"Montgomery SA, Prost JF, Solles A, Briley M (1996) Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 11(Suppl 4):47\u201351","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR100","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004714-200212000-00005","volume":"22","author":"SA Montgomery","year":"2002","unstructured":"Montgomery SA, Mahe V, Haudiquet V, Hackett D (2002) Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol 22:561\u2013567","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR101","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4088\/JCP.v65n0307","volume":"65","author":"SA Montgomery","year":"2004","unstructured":"Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL (2004) Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 65:328\u2013336","journal-title":"J Clin Psychiatry"},{"key":"164_CR102","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/YIC.0b013e32832fbb5a","volume":"24","author":"SA Montgomery","year":"2009","unstructured":"Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA (2009) Discontinuation symptoms and taper\/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 24:296\u2013305","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR103","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4088\/JCP.12m08141","volume":"74","author":"SA Montgomery","year":"2013","unstructured":"Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D (2013) Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 74:363\u2013369","journal-title":"J Clin Psychiatry"},{"key":"164_CR104","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/YIC.0000000000000009","volume":"29","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C (2014) The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 29:26\u201335","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR105","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1017\/S1092852914000273","volume":"20","author":"SA Montgomery","year":"2015","unstructured":"Montgomery SA, Gommoll CP, Chen C, Greenberg WM (2015) Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr 20:148\u2013156","journal-title":"CNS Spectr"},{"key":"164_CR106","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/0278-5846(94)90131-7","volume":"18","author":"C Moret","year":"1994","unstructured":"Moret C, Briley M (1994) Effect of milnacipran and desipramine on noradrenergic alpha 2-autoreceptor sensitivity. Prog Neuro-Psychopharmacol Biol Psychiatry 18:1063\u20131072","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"164_CR107","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/ddr.430230210","volume":"23","author":"EA Muth","year":"1991","unstructured":"Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191\u2013199","journal-title":"Drug Dev Res"},{"key":"164_CR108","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2165\/00023210-200822070-00004","volume":"22","author":"A Nakagawa","year":"2008","unstructured":"Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA (2008) Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis. CNS Drugs 22:587\u2013602","journal-title":"CNS Drugs"},{"key":"164_CR109","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0028-3908(96)84628-4","volume":"35","author":"G Neliat","year":"1996","unstructured":"Neliat G, Bodinier MC, Panconi E, Briley M (1996) Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 35:589\u2013593","journal-title":"Neuropharmacology"},{"issue":"Suppl 6","key":"164_CR110","first-page":"26","volume":"58","author":"JC Nelson","year":"1997","unstructured":"Nelson JC (1997) Safety and tolerability of the new antidepressants. J Clin Psychiatry 58(Suppl 6):26\u201331","journal-title":"J Clin Psychiatry"},{"key":"164_CR111","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archpsyc.64.4.466","volume":"64","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H, Schatzberg AF (2007) Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 64:466\u2013472","journal-title":"Arch Gen Psychiatry"},{"key":"164_CR112","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1067\/mob.2002.124840","volume":"187","author":"PA Norton","year":"2002","unstructured":"Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40\u201348","journal-title":"Am J Obstet Gynecol"},{"key":"164_CR113","first-page":"1305","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305\u20131322","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR114","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00679776","volume":"37","author":"C Palmier","year":"1989","unstructured":"Palmier C, Puozzo C, Lenehan T, Briley M (1989) Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 37:235\u2013238","journal-title":"Eur J Clin Pharmacol"},{"key":"164_CR115","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euroneuro.2006.05.001","volume":"17","author":"GI Papakostas","year":"2007","unstructured":"Papakostas GI, Fava M (2007) A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 17:32\u201336","journal-title":"Eur Neuropsychopharmacol"},{"key":"164_CR116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0897190013504957","volume":"27","author":"SH Park","year":"2014","unstructured":"Park SH, Wackernah RC, Stimmel GL (2014) Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract 27:71\u201378","journal-title":"J Pharm Pract"},{"key":"164_CR117","first-page":"667","volume":"32","author":"MH Pollack","year":"1996","unstructured":"Pollack MH, Worthington JJ 3rd, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667\u2013670","journal-title":"Psychopharmacol Bull"},{"key":"164_CR118","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","volume":"194","author":"M Pollack","year":"2007","unstructured":"Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007a) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194:233\u2013242","journal-title":"Psychopharmacology"},{"key":"164_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20218","volume":"24","author":"MH Pollack","year":"2007","unstructured":"Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B (2007b) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24:1\u201314","journal-title":"Depress Anxiety"},{"issue":"Suppl 6","key":"164_CR120","first-page":"12","volume":"56","author":"SH Preskorn","year":"1995","unstructured":"Preskorn SH (1995) Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56(Suppl 6):12\u201321","journal-title":"J Clin Psychiatry"},{"key":"164_CR121","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00131746-200411000-00006","volume":"10","author":"SH Preskorn","year":"2004","unstructured":"Preskorn SH (2004a) Duloxetine. J Psychiatr Pract 10:375\u2013385","journal-title":"J Psychiatr Pract"},{"key":"164_CR122","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00131746-200403000-00006","volume":"10","author":"SH Preskorn","year":"2004","unstructured":"Preskorn SH (2004b) Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor. J Psychiatr Pract 10:119\u2013126","journal-title":"J Psychiatr Pract"},{"issue":"Suppl","key":"164_CR123","first-page":"5","volume":"53","author":"SH Preskorn","year":"1992","unstructured":"Preskorn SH, Burke M (1992) Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 53(Suppl):5\u201318","journal-title":"J Clin Psychiatry"},{"key":"164_CR124","volume-title":"Antidepressants: past, present, and future","year":"2004","unstructured":"Preskorn SH, Jeighner JP, Stanga CY, Ross R (eds) (2004) Antidepressants: past, present, and future. Springer, Berlin"},{"key":"164_CR125","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00004850-199703000-00005","volume":"12","author":"A Puech","year":"1997","unstructured":"Puech A, Montgomery SA, Prost JF, Solles A, Briley M (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12:99\u2013108","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR126","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF03189351","volume":"23","author":"C Puozzo","year":"1998","unstructured":"Puozzo C, Albin H, Vincon G, Deprez D, Raymond JM, Amouretti M (1998a) Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 23:273\u2013279","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"164_CR127","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/BF03189352","volume":"23","author":"C Puozzo","year":"1998","unstructured":"Puozzo C, Pozet N, Deprez D, Baille P, Ung HL, Zech P (1998b) Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab Pharmacokinet 23:280\u2013286","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"164_CR128","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1080\/14656566.2017.1410540","volume":"18","author":"RM Ragguett","year":"2017","unstructured":"Ragguett RM, Yim SJ, Ho PT, McIntyre RS (2017) Efficacy of levomilnacipran extended release in treating major depressive disorder. Expert Opin Pharmacother 18:2017\u20132024","journal-title":"Expert Opin Pharmacother"},{"key":"164_CR129","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-015-3465-5","volume":"152","author":"R Ramaswami","year":"2015","unstructured":"Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B (2015) Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 152:231\u2013237","journal-title":"Breast Cancer Res Treat"},{"key":"164_CR130","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0166-4328(02)00203-6","volume":"136","author":"JP Reneric","year":"2002","unstructured":"Reneric JP, Bouvard M, Stinus L (2002) In the rat forced swimming test, chronic but not subacute administration of dual 5-HT\/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 136:521\u2013532","journal-title":"Behav Brain Res"},{"key":"164_CR131","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","volume":"157","author":"K Rickels","year":"2000","unstructured":"Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968\u2013974","journal-title":"Am J Psychiatry"},{"key":"164_CR132","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","volume":"24","author":"K Rickels","year":"2004","unstructured":"Rickels K, Mangano R, Khan A (2004) A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488\u2013496","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR133","first-page":"317","volume":"51","author":"Z Rogoz","year":"1999","unstructured":"Rogoz Z, Skuza G, Maj J (1999) Pharmacological profile of milnacipran, a new antidepressant, given acutely. Pol J Pharmacol 51:317\u2013322","journal-title":"Pol J Pharmacol"},{"key":"164_CR134","first-page":"83","volume":"52","author":"Z Rogoz","year":"2000","unstructured":"Rogoz Z, Margas W, Dlaboga D, Goralska M, Dziedzicka-Wasylewska M, Maj J (2000) Effect of repeated treatment with milnacipran on the central dopaminergic system. Pol J Pharmacol 52:83\u201392","journal-title":"Pol J Pharmacol"},{"issue":"Suppl 7","key":"164_CR135","first-page":"37","volume":"58","author":"JF Rosenbaum","year":"1997","unstructured":"Rosenbaum JF, Zajecka J (1997) Clinical management of antidepressant discontinuation. J Clin Psychiatry 58(Suppl 7):37\u201340","journal-title":"J Clin Psychiatry"},{"key":"164_CR136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","volume":"44","author":"JF Rosenbaum","year":"1998","unstructured":"Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77\u201387","journal-title":"Biol Psychiatry"},{"key":"164_CR137","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jad.2011.07.026","volume":"136","author":"G Rosso","year":"2012","unstructured":"Rosso G, Rigardetto S, Bogetto F, Maina G (2012) A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 136:172\u2013176","journal-title":"J Affect Disord"},{"key":"164_CR138","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0165-0327(99)00109-3","volume":"58","author":"F Rouillon","year":"2000","unstructured":"Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M, Smadja C, Chwalow J (2000) Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord 58:171\u2013180","journal-title":"J Affect Disord"},{"key":"164_CR139","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0165-0327(99)00067-1","volume":"56","author":"RL Rudolph","year":"1999","unstructured":"Rudolph RL, Feiger AD (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171\u2013181","journal-title":"J Affect Disord"},{"key":"164_CR140","first-page":"404","volume":"285","author":"LE Rueter","year":"1998","unstructured":"Rueter LE, De Montigny C, Blier P (1998a) Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 285:404\u2013412","journal-title":"J Pharmacol Exp Ther"},{"key":"164_CR141","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/PL00005214","volume":"357","author":"LE Rueter","year":"1998","unstructured":"Rueter LE, Kasamo K, de Montigny C, Blier P (1998b) Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedeberg\u2019s Arch Pharmacol 357:600\u2013610","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"164_CR142","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMoa052963","volume":"354","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231\u20131242","journal-title":"N Engl J Med"},{"key":"164_CR143","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/da.20271","volume":"25","author":"M Rynn","year":"2008","unstructured":"Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J (2008) Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182\u2013189","journal-title":"Depress Anxiety"},{"key":"164_CR144","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.bmcl.2010.03.059","volume":"20","author":"JP Sabatucci","year":"2010","unstructured":"Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E (2010) Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorg Med Chem Lett 20:2809\u20132812","journal-title":"Bioorg Med Chem Lett"},{"key":"164_CR145","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/JCP.0000000000000060","volume":"34","author":"A Sambunaris","year":"2014","unstructured":"Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV (2014) A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 34:47\u201356","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR146","first-page":"37","volume":"11","author":"RA Sansone","year":"2014","unstructured":"Sansone RA, Sansone LA (2014) Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci 11:37\u201342","journal-title":"Innov Clin Neurosci"},{"key":"164_CR147","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jat\/bkv134","volume":"40","author":"KA Scanlon","year":"2016","unstructured":"Scanlon KA, Stoppacher R, Blum LM, Starkey SJ (2016) Comprehensive duloxetine analysis in a fatal overdose. J Anal Toxicol 40:167\u2013170","journal-title":"J Anal Toxicol"},{"issue":"Suppl 4","key":"164_CR148","first-page":"27","volume":"67","author":"AF Schatzberg","year":"2006","unstructured":"Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC (2006) Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67(Suppl 4):27\u201330","journal-title":"J Clin Psychiatry"},{"key":"164_CR149","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00004714-199108000-00002","volume":"11","author":"E Schweizer","year":"1991","unstructured":"Schweizer E, Weise C, Clary C, Fox I, Rickels K (1991) Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 11:233\u2013236","journal-title":"J Clin Psychopharmacol"},{"key":"164_CR150","first-page":"104","volume":"55","author":"E Schweizer","year":"1994","unstructured":"Schweizer E, Feighner J, Mandos LA, Rickels K (1994) Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55:104\u2013108","journal-title":"J Clin Psychiatry"},{"key":"164_CR2006","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/00912700022008810","volume":"40","author":"A Sharma","year":"2000","unstructured":"Sharma A, Goldberg MJ, Cerimele BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161\u2013167","journal-title":"J Clin Pharmacol"},{"key":"164_CR151","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1185\/03007990802293643","volume":"24","author":"DV Sheehan","year":"2008","unstructured":"Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, Mallinckrodt CH (2008) The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 24:2457\u20132466","journal-title":"Curr Med Res Opin"},{"key":"164_CR152","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.4088\/JCP.14com09586","volume":"76","author":"RC Shelton","year":"2015","unstructured":"Shelton RC (2015) What are the comparative benefits and harms of augmentation treatments in major depression? J Clin Psychiatry 76:e531\u2013e533","journal-title":"J Clin Psychiatry"},{"key":"164_CR153","first-page":"10","volume":"11","author":"T Shiovitz","year":"2014","unstructured":"Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll CP (2014) A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran er 40-120\u00a0mg\/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci 11:10\u201322","journal-title":"Innov Clin Neurosci"},{"key":"164_CR154","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/JCP.v60n0105","volume":"60","author":"PH Silverstone","year":"1999","unstructured":"Silverstone PH, Ravindran A (1999) Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 60:22\u201328","journal-title":"J Clin Psychiatry"},{"key":"164_CR155","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1067\/mcp.2003.28","volume":"73","author":"MH Skinner","year":"2003","unstructured":"Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73:170\u2013177","journal-title":"Clin Pharmacol Ther"},{"key":"164_CR156","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000139514","volume":"55","author":"JE Smith","year":"1997","unstructured":"Smith JE, Lakoski JM (1997) Electrophysiological study of the effects of the reuptake inhibitor duloxetine on serotonergic responses in the aging hippocampus. Pharmacology 55:66\u201377","journal-title":"Pharmacology"},{"key":"164_CR157","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003495-199856030-00010","volume":"56","author":"CM Spencer","year":"1998","unstructured":"Spencer CM, Wilde MI (1998) Milnacipran. A review of its use in depression. Drugs 56:405\u2013427","journal-title":"Drugs"},{"key":"164_CR158","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","volume":"26","author":"E Spina","year":"2012","unstructured":"Spina E, Trifiro G, Caraci F (2012) Clinically significant drug interactions with newer antidepressants. CNS Drugs 26:39\u201367","journal-title":"CNS Drugs"},{"key":"164_CR159","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00004850-199709000-00004","volume":"12","author":"A Steen","year":"1997","unstructured":"Steen A, Den Boer JA (1997) A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 12:269\u2013281","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR160","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00217054","volume":"91","author":"A Stenger","year":"1987","unstructured":"Stenger A, Couzinier JP, Briley M (1987) Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology 91:147\u2013153","journal-title":"Psychopharmacology"},{"key":"164_CR161","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","volume":"54","author":"JR Strawn","year":"2015","unstructured":"Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL (2015) A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 54:283\u2013293","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"164_CR162","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000348564","volume":"75","author":"Z Sun","year":"2013","unstructured":"Sun Z, Hao Y, Zhang M (2013) Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Investig 75:255\u2013262","journal-title":"Gynecol Obstet Investig"},{"issue":"Suppl 1","key":"164_CR163","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/00004850-200206001-00005","volume":"17","author":"O Tajima","year":"2002","unstructured":"Tajima O (2002) Japanese experience with dual-action antidepressants. Int Clin Psychopharmacol 17(Suppl 1):S37\u2013S42","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR164","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/WNF.0b013e3181a8c84f","volume":"32","author":"S Tarlaci","year":"2009","unstructured":"Tarlaci S (2009) Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 32:254\u2013258","journal-title":"Clin Neuropharmacol"},{"key":"164_CR165","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4088\/JCP.v58n0904","volume":"58","author":"ME Thase","year":"1997","unstructured":"Thase ME (1997) Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 58:393\u2013398","journal-title":"J Clin Psychiatry"},{"key":"164_CR166","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1185\/03007995.2015.1020365","volume":"31","author":"ME Thase","year":"2015","unstructured":"Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA (2015) Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin 31:809\u2013820","journal-title":"Curr Med Res Opin"},{"key":"164_CR167","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0447.1998.tb09980.x","volume":"97","author":"J Tignol","year":"1998","unstructured":"Tignol J, Pujol-Domenech J, Chartres JP, Leger JM, Pletan Y, Tonelli I, Tournoux A, Pezous N (1998) Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 97:157\u2013165","journal-title":"Acta Psychiatr Scand"},{"key":"164_CR168","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.clinthera.2017.05.347","volume":"39","author":"AP Trouvin","year":"2017","unstructured":"Trouvin AP, Perrot S, Lloret-Linares C (2017) Efficacy of venlafaxine in neuropathic pain: a narrative review of optimized treatment. Clin Ther 39:1104\u20131122","journal-title":"Clin Ther"},{"key":"164_CR169","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0893-133X(00)00220-7","volume":"24","author":"JE Turcotte","year":"2001","unstructured":"Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P (2001) Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24:511\u2013521","journal-title":"Neuropsychopharmacology"},{"key":"164_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.12216","volume":"40","author":"LA VanderWeide","year":"2015","unstructured":"VanderWeide LA, Smith SM, Trinkley KE (2015) A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther 40:1\u20136","journal-title":"J Clin Pharm Ther"},{"issue":"25","key":"164_CR1000","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1161\/01.CIR.0000130847.18666.39","volume":"109","author":"Simi Vincent","year":"2004","unstructured":"Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D (2004) Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109:3202\u20133207","journal-title":"Circulation"},{"key":"164_CR171","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","volume":"171","author":"CS Voican","year":"2014","unstructured":"Voican CS, Corruble E, Naveau S, Perlemuter G (2014) Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 171:404\u2013415","journal-title":"Am J Psychiatry"},{"key":"164_CR172","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004850-199001000-00005","volume":"5","author":"R von Frenckell","year":"1990","unstructured":"von Frenckell R, Ansseau M, Serre C, Sutet P (1990) Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 5:49\u201356","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2017.11.056","volume":"228","author":"G Wagner","year":"2017","unstructured":"Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G (2017) Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. J Affect Disord 228:1\u201312","journal-title":"J Affect Disord"},{"key":"164_CR174","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/ALN.0b013e3181e89a93","volume":"113","author":"SY Wang","year":"2010","unstructured":"Wang SY, Calderon J, Kuo Wang G (2010) Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113:655\u2013665","journal-title":"Anesthesiology"},{"key":"164_CR175","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1213\/ANE.0000000000000794","volume":"121","author":"CF Wang","year":"2015","unstructured":"Wang CF, Russell G, Strichartz GR, Wang GK (2015) The local and systemic actions of duloxetine in allodynia and hyperalgesia using a rat skin incision pain model. Anesth Analg 121:532\u2013544","journal-title":"Anesth Analg"},{"key":"164_CR176","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1213\/ANE.0000000000001086","volume":"122","author":"CF Wang","year":"2016","unstructured":"Wang CF, Russell G, Wang SY, Strichartz GR, Wang GK (2016) R-duloxetine and N-methyl duloxetine as novel analgesics against experimental postincisional pain. Anesth Analg 122:719\u2013729","journal-title":"Anesth Analg"},{"key":"164_CR177","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/YIC.0000000000000157","volume":"32","author":"KA Wesnes","year":"2017","unstructured":"Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS, Harvey PD (2017) Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study. Int Clin Psychopharmacol 32:72\u201379","journal-title":"Int Clin Psychopharmacol"},{"key":"164_CR178","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/0024-3205(88)90579-6","volume":"43","author":"DT Wong","year":"1988","unstructured":"Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR (1988) LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci 43:2049\u20132057","journal-title":"Life Sci"},{"key":"164_CR179","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.1993.4","volume":"8","author":"DT Wong","year":"1993","unstructured":"Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23\u201333","journal-title":"Neuropsychopharmacology"},{"key":"164_CR180","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hup.432","volume":"17","author":"K Yoshida","year":"2002","unstructured":"Yoshida K, Higuchi H, Takahashi H, Shimizu T (2002) Elevation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol 17:431","journal-title":"Hum Psychopharmacol"},{"key":"164_CR181","first-page":"285","volume":"73","author":"L Zadka","year":"2016","unstructured":"Zadka L, Dziwota E, Olajossy M (2016) Levomilnacipran--a successor of milnacipran with a higher noradrenergic selectivity. Acta Pol Pharm 73:285\u2013289","journal-title":"Acta Pol Pharm"}],"container-title":["Handbook of Experimental Pharmacology","Antidepressants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2018_164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:09:20Z","timestamp":1649894960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2018_164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783030109486","9783030109493"],"references-count":184,"URL":"https:\/\/doi.org\/10.1007\/164_2018_164","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"6 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}